Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BioNTech : EMA - Two additional manufacturing sites for BioNTech Pfizer's COVID-19 vaccine

06/23/2021 | 10:17am EDT

EMA's committee for human medicines (CHMP) has approved additional manufacturing sites for the production of Comirnaty, the COVID-19 vaccine developed by BioNTech and Pfizer.

One site, located in Reinbek, Germany, is operated by Allergopharma GmbH & Co. KG. The other in Stein, Switzerland, is operated by Novartis Pharma. The sites will perform finished product manufacturing steps at different stages of the process.

The two new sites are expected to support the continued supply of Comirnaty in the European Union.

This recommendation does not require a European Commission decision and the sites can become operational immediately.

The changes described will be included in the publicly available information on this vaccine.

Related content

Comirnaty: EPAR

Comirnaty: Paediatric investigation plan

Related content

Coronavirus disease (COVID-19)

COVID-19: latest updates

COVID-19 vaccines: authorised

COVID-19 vaccines: development, evaluation, approval and monitoring

Contact:

Tel: +31 (0)88 781 8427

Email: press@ema.europa.eu

(C) 2021 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE -3.49% 401 Delayed Quote.408.39%
PFIZER, INC. -0.94% 44.8 Delayed Quote.22.77%
All news about BIONTECH SE
11:08aBIONTECH : Completes Acquisition of Kite's Neoantigen TCR Cell Therapy R&D Platf..
AQ
11:08aEuropean ADRs Move Higher in Thursday Trading
MT
08:59aMODERNA : says its COVID-19 shot 93% effective six months after second dose
RE
12:08aPFIZER : to Require COVID-19 Shots or Regular Testing for US Workers
MT
08/04BIONTECH : Completes Acquisition of Gilead Subsidiary's Neoantigen TCR Cell Ther..
MT
08/04European ADRs Move Slightly Higher in Wednesday Trading
MT
08/04GLOBAL MARKETS LIVE : Novartis, Apple, Commerzbank, Amgen, Lyft...
08/04PFIZER : South Africa quickens vaccine drive, gets more doses from US
AQ
08/04BIONTECH : completes Acquisition of Kite's Neoantigen TCR Cell Therapy R&D Platf..
PU
08/04MARKET CHATTER : Thonburi Healthcare Faces Regulatory Pressure on Purported Vacc..
MT
More news
Financials
Sales 2021 13 071 M 15 472 M 15 472 M
Net income 2021 7 590 M 8 984 M 8 984 M
Net cash 2021 8 581 M 10 158 M 10 158 M
P/E ratio 2021 11,6x
Yield 2021 -
Capitalization 84 562 M 100 B 100 B
EV / Sales 2021 5,81x
EV / Sales 2022 5,94x
Nbr of Employees 2 200
Free-Float 87,3%
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Last Close Price 350,12 €
Average target price 165,41 €
Spread / Average Target -52,8%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Jens Holstein Chief Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Ízlem TŘreci Chief Medical Officer
Sierk P÷tting Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE408.39%100 096
GILEAD SCIENCES, INC.19.86%86 839
WUXI APPTEC CO., LTD.41.52%72 049
REGENERON PHARMACEUTICALS21.40%60 161
VERTEX PHARMACEUTICALS-15.55%51 779
BEIGENE, LTD.32.78%31 922